Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial

被引:195
|
作者
Grotta, JC
Welch, KMA
Fagan, SC
Lu, M
Frankel, MR
Brott, T
Levine, SR
Lyden, PD
机构
[1] Univ Texas, Sch Med, Dept Neurol, Stroke Program, Houston, TX 77030 USA
[2] Henry Ford Hlth Sci Ctr, Dept Biostat & Res Epidemiol, Detroit, MI USA
[3] Henry Ford Hlth Sci Ctr, Dept Pharm Serv, Detroit, MI USA
[4] Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA
[5] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA
[6] Univ Cincinnati, Sch Med, Dept Neurol, Cincinnati, OH USA
[7] Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA
[8] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA
关键词
deterioration; reocclusion; stroke; thrombolysis;
D O I
10.1161/01.STR.32.3.661
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-Little is known in regard to cerebral arterial reocclusion after successful thrombolysis. In the absence of arteriographic information, the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Trial investigators prospectively identified clinical deterioration following improvement (DFI) as a possible surrogate marker of cerebral arterial reocclusion after rt-PA-induced recanalization. Also, we identified any significant clinical deterioration (CD) even if not preceded by improvement. This observational analysis was designed to determine the incidence of DFI and CD in each treatment group, to identify baseline or posttreatment variables predictive of DFI or CD, and to determine any relationship between DFI, CD, and clinical outcome. Methods-DFI was defined as any 2-point deterioration on the NIH Stroke Scale after an initial 2-point improvement after treatment. CD was defined as any 4-point worsening after treatment compared with baseline. All data were collected prospectively by investigators blinded to treatment allocation. A noncontrast brain CT was mandated when a 2-point deterioration occurred. All cases were validated by a central review committee. Results-DFI was identified in 81 of the 624 patients (13%); 44 were treated with rt-PA and 37 were treated with placebo (P=0.48). DFI occurred more often in patients with a higher baseline NIH Stroke Scale score. CD within the first 24 hours occurred in 98 patients (16% of all patients); 43 were given rt-PA and 55 were given placebo (P=0.19). Baseline variables associated with CD included a less frequent use of prestroke aspirin and a higher incidence of early CT changes of edema or mass effect or dense middle cerebral artery sign. Patients with CD had higher rates of increased serum glucose and fibrin degradation products, and they also had higher rates of symptomatic intracranial hemorrhage and death. Patients who experienced either DFT or CD were less likely to have a 3-month favorable outcome. Conclusions-We found no association between DFI, CD, and rt-PA treatment, and no clinical evidence to suggest reocclusion. Deterioration was strongly associated with stroke severity and poor outcome and was less frequent in patients whose stroke occurred while they were on aspirin.
引用
收藏
页码:661 / 668
页数:8
相关论文
共 50 条
  • [31] Use of rt-PA in acute stroke
    不详
    AMERICAN JOURNAL OF NURSING, 2006, 106 (07) : 72AA - 72BB
  • [32] Redefined Measure of Early Neurological Improvement Shows Treatment Benefit of Intravenous Tissue Plasminogen Activator Treatment in NINDS Rt-PA Acute Stroke Trial at 24 Hours
    Agarwal, Shashank
    Scher, Erica
    Lord, Aaron
    Frontera, Jennifer
    Ishida, Koto
    Torres, Jose
    Rostanski, Sara
    Mistry, Eva
    Mac Grory, Brian C.
    Cutting, Shawna
    Burton, Tina
    Silver, Brian
    Liberman, Ava L.
    Mackenzie, P. Mackenzie
    Furie, Karen
    Grotta, James
    Khatri, Pooja
    Saver, Jeffrey L.
    Yaghi, Shadi
    STROKE, 2020, 51
  • [33] Relating ASPECTS infarct location to stroke disability in the NINDS rt-PA trial: proof of concept study using penalized logistic regression
    Phan, T. G.
    Demchuk, A.
    Srikanth, V.
    Silver, B.
    Patel, S.
    Barber, P. A.
    Levine, S. R.
    Hill, M.
    CEREBROVASCULAR DISEASES, 2013, 35 : 407 - 407
  • [34] rt-PA reduces length of stay and improves disposition following stroke
    Fagan, SC
    Morgenstern, LB
    Petitta, A
    Ward, RE
    Tilley, BC
    Marler, JR
    Broderick, JP
    Levine, SR
    STROKE, 1997, 28 (01) : 211 - 211
  • [35] Angioneurotic orolingual edema associated with the use of rt-PA following a stroke
    Laubinger, R.
    Guthke, K.
    Erdmann, U.
    Klein, U.
    ANAESTHESIST, 2007, 56 (10): : 1024 - 1027
  • [36] The ATLANTIS rt-PA (Alteplase) acute stroke trial: Final results
    Clark, WM
    Albers, GW
    STROKE, 1999, 30 (01) : 234 - 234
  • [37] Extraischemic Hematomas Following Intravenous rt-PA For Acute Ischemic Stroke
    Osaki, Masato
    Koga, Masatoshi
    Fukuda, Mayumi
    Shigehatake, Yuya
    Nagatsuka, Kazuyuki
    Minematsu, Kazuo
    Toyoda, Kazunori
    STROKE, 2013, 44 (02)
  • [38] AN OPEN MULTICENTER TRIAL OF RT-PA IN ACUTE STROKE - SAFETY AND EFFICACY
    DELZOPPO, GJ
    POECK, K
    PESSIN, MS
    FURLAN, A
    ZIVIN, J
    KASE, C
    GRESS, D
    MOHR, JP
    THROMBOSIS AND HAEMOSTASIS, 1989, 62 (01) : 27 - 27
  • [39] Importance of leukoaraiosis on CT for tissue plasminogen activator decision making: Evaluation of the NINDS rt-PA Stroke Study
    Demchuk, Andrew M.
    Khan, Firosh
    Hill, Michael D.
    Barber, Philip A.
    Silver, Brian
    Patel, Suresh
    Levine, Steven R.
    CEREBROVASCULAR DISEASES, 2008, 26 (02) : 120 - 125
  • [40] Stroke treatment in the community (STIC) - Intravenous rt-PA in clinical practice
    Hanson, SK
    Brauer, DJ
    Anderson, DC
    Koller, RL
    Davenport, JG
    Ramirez-Lassepas, M
    Klassen, AC
    Altafullah, IM
    Brown, RD
    NEUROLOGY, 1998, 50 (04) : A155 - A156